PMS2 (EPR3947) Rabbit Monoclonal Antibody

PMS2
Nuclear labelling of carcinoma cells by PMS2 antibody on colon adenocarcinoma.

PMS2 (EPR3947) Rabbit Monoclonal Antibody

Specialties: Gastrointestinal (GI) Pathology

Updated: 2018-01-24 14:37:01

PMS2 is a mismatch repair protein that is deficient in a high proportion of patients with microsatellite instability (MSI-H). It has been suggested that the deficiencies in DNA mismatch repair protein(s) can be seen in some malignancies such as hereditary nonpolyposis colorectal cancer (HNPCC) and endometrial cancer. Anti-PMS2 may be useful in the identification of the PMS2 protein in a variety of normal and neoplastic tissues and the  identification of loss of MLH1 in tumors with MSI genotype.1-7 Anti-PMS2 is best utilized in an IHC panel that includes anti-MSH6, anti-MSH2, and anti-MLH1.

  1. Gologan A, et al. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. Clin Lab Med. 2005; 25:179-96.
  2. Lagerstedt Robinson K, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 2007; 99:291-9.
  3. Hendriks YM, et al. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology. 2006; 130:312-22.
  4. Truninger K, et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology. 2005; 128:1160-71.
  5. Hampel H, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352:1851-60.
  6. Warusavitarne J, et al. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis. 2007; 22:739-48.
  7. Gill S, et al. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res. 2005; 11:6466-71.

Specifications


  • Reactivity: paraffin
  • Control: Colon (Nuclear)
  • Dilution Range: N/A *

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

25.0 mL predilute ready-to-use288R-10
1.0 mL predilute ready-to-use288R-17
7.0 mL predilute ready-to-use288R-18

For in vitro diagnostic (IVD) use in Canada

25.0 mL predilute ready-to-use288R-10
1.0 mL predilute ready-to-use288R-17
7.0 mL predilute ready-to-use288R-18

For in vitro diagnostic (IVD) use in Europe

25.0 mL predilute ready-to-use288R-10
1.0 mL predilute ready-to-use288R-17
7.0 mL predilute ready-to-use288R-18

For research use only (RUO) in Japan

25.0 mL predilute ready-to-use (RUO)288R-10-RUO
1.0 mL predilute ready-to-use (RUO)288R-17-RUO
7.0 mL predilute ready-to-use (RUO)288R-18-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information